Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaxoSmithKline PakistanKAR:GLAXO 93 5-Year Yield-on-Cost % is 4.82 as of Jul. 17, 2026, which is 18% above its 10-year median of 4.07. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.76 (Fairly Valued). The stock has 1 warning sign investors should review. Among 514 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 71.79% on this metric.
The historical rank and industry rank for GlaxoSmithKline Pakistan's 5-Year Yield-on-Cost % or its related term are showing as below:
KAR:GLAXO'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.51 Med: 4.07 Max: 9.69
Current: 4.82
During the past 13 years, GlaxoSmithKline Pakistan's highest Yield on Cost was 9.69. The lowest was 1.51. And the median was 4.07.
KAR:GLAXO's 5-Year Yield-on-Cost % is ranked better than 71.79% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs KAR:GLAXO: 4.82
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
GlaxoSmithKline Pakistan 5-Year Yield-on-Cost % Related Terms
KAR:GLAXO vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a 5-Year Yield-on-Cost % of 4.82 as of Jul. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 18% above median its historical median of 4.07. Over the past decade, GlaxoSmithKline Pakistan's 5-Year Yield-on-Cost % has ranged from 1.51 to 9.69. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #145 out of 514 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is GlaxoSmithKline Pakistan's 5-Year Yield-on-Cost % too high?
GlaxoSmithKline Pakistan's current 5-Year Yield-on-Cost % of 4.82 is 18% above median its 10-year median of 4.07. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 9.69. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.33. GlaxoSmithKline Pakistan's value of 4.82 is 107.3% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #145 out of 514 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #145 out of 514 companies for 5-Year Yield-on-Cost %. This puts GlaxoSmithKline Pakistan in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. GlaxoSmithKline Pakistan's value of 4.82 is 107.3% above this benchmark. Historically, GlaxoSmithKline Pakistan's own 5-Year Yield-on-Cost % has ranged from 1.51 to 9.69 over the past decade. While the company's 10-year median is 4.07 vs. the industry median of 2.33, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.33, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current 5-Year Yield-on-Cost % of 4.82 is 107.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current 5-Year Yield-on-Cost % is 4.82, which is 18% above median its own 10-year median of 4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₨323.76, compared to a current price of ₨352.64 — trading 8.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 4.82, which is 18% above median its 10-year median of 4.07 and 107.3% above the Drug Manufacturers industry median of 2.33. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current 5-Year Yield-on-Cost % is 4.82 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨352.64 is trading 8.9% above its estimated GF Value™ of ₨323.76.
GuruFocus considers GlaxoSmithKline Pakistan to be Fairly Valued.
Key valuation signals for KAR:GLAXO:
5-Year Yield-on-Cost %: 4.82 (18% above median its 10-year median of 4.07)
GF Value™: ₨323.76 vs. price of ₨352.64 (8.9% above fair value)
Industry Position: 107.3% above the Drug Manufacturers median (#145 of 514)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score
Get the complete analysis for KAR:GLAXO
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
